News for Arbutus Biopharma Corporation (0SGC.L)

BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with

**media[555746]**

**media[555742]**

WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS) (”œArbutus” or the ”œCompany”), a clinical-stage biopharmaceut

Chris DeMuth, Jr. shares what's special about Arbutus, Burford Capital, and Cadiz and why an M&A boom is coming.

**media[513454]**

Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon

Whitefort Capital Management, LP (together with its affiliates, ”œWhitefort Capital,” ”œus” or ”œwe”), which is a long-term investor and the third lar

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ( ABUS), (”œArbutus” or the ”œCompany”), a clinical-stage biopharmaceut

**media[476552]**

New trial shows promise for chronic hepatitis B treatment

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial

Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared to other cohorts asse…

Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2024 Results Conference Call November 6, 2024 8:45 AM ETCompany ParticipantsLisa Caperelli - VP, Investor...

OXFORD, United Kingdom, March 20, 2024 -- Barinthus Biotherapeutics plc , formerly Vaccitech plc, announced its financial results for the year ended December 31, 2023, and an overview of the...

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101

On-track to report key clinical data in 2024 from two on-going Phase 2a clinical trials with imdusiran and the Phase 1a/1b clinical trial with AB-101 Plans to initiate a third Phase 2a clinical...

Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi…

The RNA interference therapy pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming...